Compare · INCY vs ISPC
INCY vs ISPC
Side-by-side comparison of Incyte Corp. (INCY) and iSpecimen Inc. (ISPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and ISPC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $20.45B, about 4712.0x ISPC ($4.3M).
- Over the past year, INCY is up 44.1% and ISPC is down 94.0% - INCY leads by 138.1 points.
- INCY has been more active in the news (16 items in the past 4 weeks vs 4 for ISPC).
- INCY has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- Incyte Corp.
- iSpecimen Inc.
- Price
- $100.66-1.64%
- $2.97-1.33%
- Market cap
- $20.45B
- $4.3M
- 1M return
- +2.99%
- -43.21%
- 1Y return
- +44.11%
- -94.01%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 2
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest INCY
- Principal Accounting Officer Tray Thomas sold $263,900 worth of shares (2,639 units at $100.00) and exercised 2,639 shares at a strike of $83.83 (SEC Form 4)
- Incyte Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
- Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
- President, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 25,469 shares, decreasing direct ownership by 10% to 240,848 units (SEC Form 4) to cover taxes
- Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
- Principal Accounting Officer Tray Thomas sold $199,665 worth of shares (2,051 units at $97.35), decreasing direct ownership by 9% to 21,132 units (SEC Form 4)
- Director Bienaime Jean Jacques exercised 15,000 shares at a strike of $84.53 and covered exercise/tax liability with 13,059 shares, increasing direct ownership by 9% to 22,782 units (SEC Form 4)
- SEC Form DEFA14A filed by Incyte Corp.
- Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Latest ISPC
- SEC Form S-3 filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by iSpecimen Inc.
- SEC Form D filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
- iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
- iSpecimen Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Other Events